SGLT2 inhibitors ’ interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn

The first cardiovascular (CV) safety trial conducted with a sodium-glucose cotransporter (SGLT)-2 inhibitor, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients —Removing Excess Glucose (EMPA-REG OUTCOME), reported not only remarkable risk reductions in CV outcome, but also impressive improvements in renal outcome. Changes in renal hemodynamics could be involved in the benefit of SGLT2 inhibitors on renal outcomes. Considering that all patients of EMPA-RE G OUTCOME had established atherosclerotic CV disease at baseline, many patients were also treated with several CV drugs at baseline, including RAS blockers, diuretics, calcium-channel blockers, and nonsteroidal anti-inflammatory drugs.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Commentary Source Type: research

Related Links:

AbstractPurpose of ReviewChildren and adolescents with acute hyperglycemia and diabetes mellitus frequently have acute, potentially life-threatening presentations which require high-acuity care in an inpatient and often intensive care setting. This review discusses the evaluation and care of hyperglycemia and diabetes mellitus in hospitalized children in both critical and non-critical care settings, highlighting important differences in their care relative to adults.Recent FindingsDiabetic ketoacidosis remains highly prevalent at diagnosis among children with type 1 diabetes, and hyperglycemic hyperosmolar state is increas...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
Publication date: Available online 21 August 2019Source: Artificial Intelligence in MedicineAuthor(s): Sebastian Spänig, Agnes Emberger-Klein, Jan-Peter Sowa, Ali Canbay, Klaus Menrad, Dominik HeiderAbstractArtificial intelligence (AI) will pave the way to a new era in medicine. However, currently available AI systems do not interact with a patient, e.g., for anamnesis, and thus are only used by the physicians for predictions in diagnosis or prognosis. However, these systems are widely used, e.g., in diabetes or cancer prediction.In the current study, we developed an AI that is able to interact with a patient (virtual...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
WEDNESDAY, Aug. 21, 2019 -- Middle-aged women with type 2 diabetes mellitus (T2DM) have more sleep disturbances than women without diabetes, even when accounting for menopause and other health issues, according to a study published online Aug. 12 in...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
Source: BMJ - Category: General Medicine Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Nature Reviews Endocrinology, Published online: 22 August 2019; doi:10.1038/s41574-019-0242-2Metformin is the first-line drug for treatment of type 2 diabetes mellitus (T2DM) and is effective in decreasing plasma glucose levels. This review summarizes the glucoregulatory mechanisms of metformin in T2DM and highlights emerging evidence that metformin decreases obesity-induced meta-inflammation and acts in the gastrointestinal tract.
Source: Nature Reviews Endocrinology - Category: Endocrinology Authors: Source Type: research
ConclusionsThe algorithm produces plausible analyses of medication errors in older people, pointing to established areas of therapeutic deficiencies. Though individual recommendations exist, the algorithm cannot employ the full potential of FORTA as important details (e.g., blood pressure values, pain intensity) are not (yet) included. However, it seems capable of detecting medication problems in large cohorts —FORTA-EPI (Epidemiological) is designed to support epidemiological analyses, e.g., on comparisons of large cohorts, interventional impact, or longitudinal trends.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
This article describes the concept and design of the trial evaluating the efficacy of this education program called “DiaLife—Living Together with Diabetes”.MethodsThis evaluation study is a cluster randomized controlled trial, in which the study centers will be randomly assigned either to the intervention group or the control group. Study centers will recruit relatives of and patients with DM type 1 and type 2. Members of the intervention group will participate in the education program DiaLife, whereas participants randomized in the control group will act as waiting-list controls. The study will assess th...
Source: Trials - Category: Research Source Type: clinical trials
Although control of chronic glycemia in the population with diabetes and end-stage renal disease (ESRD) has been extensively studied in recent years, the unique problems of short-term glycemic management in acutely ill patients undergoing dialysis have received little attention. Bally et  al. evaluated the role of a “closed-loop” (glucose sensor/algorithm tablet device/insulin pump) system in a cohort of hospitalized patients with type 2 diabetes receiving hemodialysis. Compared with usual care, the intervention group had superior glycemic control without increased hypoglycemic events.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Commentary Source Type: research
Authors: Carretero-Anibarro E, Hamud-Uedha M PMID: 31427152 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
More News: Calcium | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance | Learning | SGLT2 Inhibitors | Sodium | Universities & Medical Training | Urology & Nephrology